Tay-Sachs disease is a rare, fatal genetic disorder that is caused by the lack of an enzyme called hexosaminidase A. It primarily affects Ashkenazi Jewish populations and people of French-Canadian or Cajun heritage. The disease causes harmful ganglioside buildup in neurons which leads to progressive damage to the nervous system and loss of physical and mental abilities over time, ultimately resulting in death in childhood. There is currently no treatment or way to prevent the progression of Tay-Sachs disease.

1. In AD, many of these clumps form, disrupting the work of neurons. This By: Víctor Ramos Almirón

2. What is TSD? Is a rare disease that affects the central nervous system and is of hereditary character, autosomal and recessive, that causes severe collateral effects, both physical and mental.

4. Causes of Tay-Sachs The disease is caused by mutations on chromosome 15 in the HEX A gene, which produces a lack of hexosaminidase A.

5. Without this enzyme, gangliosides, particularly ganglioside GM2, increases and degenerates central nervous system.

6. Signs or Symptoms Tay–Sachs disease is classified in variant forms, based on the time of onset of neurological symptoms. Infantile JuvenileAdult/Late Onset 3 to 10 months two and 10 years 20 and 30 years Extremely rare usually non-fatal

7. Signs or Symptoms -Loss of learned skills-Loss of smile, crawl, grab.-Blindness, Deafness, Paralysis.-Dementia -Unable to swallow -Muscle atrophy -Cherry-red spot in the back of their eyes

8. -Treatment There is no treatment for Tay-Sachs disease, nor there is any way to prevent or reduce the progression of this disorder.

9. CLINICAL CASE Lactante of a year of age, masculine sex, half-caste, natural race of Lima with time of disease of 8 months that according to the mother begins with "frights" (stretches arms and legs to any noise), progressive loss of muscular force and impede to support the head and the thorax. At 8 months old loss of vision accompanied by progressive spasticity from the low members and recurrent bronchitis.

10. Examination Fund of eye: presence of bilateral pallor of papila and cherry-red spot in the macula. Biochemicalprofile: Total Hexosaminidase 125.0 nM, Hexosaminidase A: 0%. Other bloodtests withoutsignificantalterations. The patient evolved with physical and neurological progressive deterioration, beingdiagnosedwith TSD Slide 39

11. THE END